Worth Observing Stocks: Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP), CVS Health Corporation (NYSE:CVS)

u.s stocks update

Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP)

The company announced its last quarter financial performance results on 11/07/2016. Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) belongs to Medical sector that surged 0% in value when last trading session closed at $5.92. The company has a market capitalization of $875.15 Million. The company’s stock has a Return on Assets (ROA) of -146.3 percent, a Return on Equity (ROE) of 0 percent and Return on Investment (ROI) of 0 percent. The company reached its 52-Week high of $6.29 on Dec 9, 2016 and 52-Week low of $2.5 on Mar 23, 2016.

Earnings per share (ttm) for Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) according to Finviz Data is $-1.23.

This company was Downgrade by Citigroup on 18-Dec-15  to Neutral.

The 5 analysts offering 12-month price forecasts for Synergy Pharmaceuticals Inc have a median target of 11.00, with a high estimate of 17.00 and a low estimate of 6.50. The median estimate represents a +85.81% increase from the last price of 5.92.

Financial History:

Following Earnings result, share price were DOWN 7 times out of last 10 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 33% percent of times. It has met expectations  1 times and missed earnings  7  times.

The consensus recommendation for Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) is 1. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 1. In comparison, the consensus recommendation 60 days ago was at 1, and 90 days ago was at 1 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects Synergy Pharmaceuticals, Inc. to have earnings per share of $-0.2.

Company Profile:

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York.

CVS Health Corporation (NYSE:CVS):

CVS Health Corporation (NYSE:CVS) belongs to Retail-Wholesale sector closed its last session with a loss of -0.05 percent and closed its previous trading session at $79. According to Finviz reported data, the stock currently has Earnings per Share (EPS) (ttm) of $4.69. The company has the Market capitalization of $84.37 Billion. The company’s stock has a Return on Assets (ROA) of 5.1 percent, a Return on Equity (ROE) of 13.2 percent and Return on Investment (ROI) of 9.4 percent. The company reached its 52-Week high of $106.67 on May 9, 2016 and 52-Week low of $69.3 on Nov 8, 2016.

The growth estimate for CVS Health Corporation (NYSE:CVS) for the current quarter is 9.2 percent. The projected growth estimate for the next quarter is -3.4 percent. The company’s stock has grown by 14.4 percent in the past 5 years. For the next 5 years, the company is expected to grow by 10.69 percent.

This company was Downgrade by Jefferies on 12-Dec-16 to Hold.

The 23 analysts offering 12-month price forecasts for CVS Caremark have a median target of 88.00, with a high estimate of 114.00 and a low estimate of 81.00. The median estimate represents a +11.39% increase from the last price of 79.00.

Financial History:

Following Earnings result, share price were UP 17 times out of last 27 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 66% percent of times. It has met expectations  2  times and missed earnings  2  times.

The consensus recommendation for CVS Health Corporation (NYSE:CVS) is 1.61. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 1.45. In comparison, the consensus recommendation 60 days ago was at 1.47, and 90 days ago was at 1.47 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects CVS Health Corporation to have earnings per share of $1.67.

Revenue is expected to range from 45.83 Billion to 47.61 Billion with an average of 46.54 Billion.

Company Profile:

CVS Health Corporation is a pharmacy innovation company. Its offerings include pharmacy benefit management services, mail order, retail and specialty pharmacy, disease management programs, and retail clinics. The Company serves employers, insurance companies, unions, government employee groups, managed care organizations and other sponsors of health benefit plans, and individuals under the CVS Caremark Pharmacy Services, Caremark, CVS Caremark, CarePlus CVS/pharmacy, RxAmerica, Accordant, SilverScript, and Novologix names. CVS Health Corporation, formerly known as CVS Caremark Corporation, is headquartered in Woonsocket, Rhode Island.